Loading…
← CockpitCompetitor Analysis › ASTRAZEN.NS AstraZeneca Pharma India LimitedOpen in the cockpit ↗

AstraZeneca Pharma India LimitedASTRAZEN.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.

≈ AstraZeneca's Indian pharma subsidiaryMomentum laggard 9
Mkt cap
$1.62B
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$904,339
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+34.2 pp
WACC 14.0%
Hurdle
+19 pp
Req g minus delivered
Close · INR₹6,044
1D-2.0%
1W-7.1%
1M+0.1%
3M-20.9%
6M-30.5%
YTD-33.1%
1Y-34.9%
ATR %3.8%
Beta0.51
52w lowhigh36.2% off high

What AstraZeneca Pharma India does

Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.

Markets its parent's patented medicines in India rather than discovering most of them itself, so launches depend on regulatory approvals and on what the parent chooses to bring to the Indian market. AstraZeneca plc holds a majority stake.

In one line: AstraZeneca's Indian pharma subsidiary.

Products and services

  • Oncology brands
  • Diabetes/respiratory drugs
  • Cardiovascular products

Customers

  • Hospitals/oncologists
  • Retail pharmacies

Where it sits in the supply chain

  • Global AstraZeneca R&D
  • Local formulation/packaging
  • Branded pharma distribution

What could go right

  • Oncology/specialty drug volume growth
  • New product launches from AZ pipeline

What could go wrong

  • Government price controls
  • Generic competition after patent expiry

Moat: narrow (brand, IP / patents). Access to AstraZeneca's global oncology and specialty pipeline, though the Indian entity is a small local unit.

Headquarters: Bengaluru, India · Founded: 1979 · Employees: 760

Named competitors

AstraZeneca Pharma India at a glance

Size AstraZeneca Pharma India (ASTRAZEN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.62B, the 445th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹6,044 on 18 Nov 2026.

Performance Over six months the shares fell 30.5%, against -3.7% for the median peer and +3.8% for the India market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 29.7% over the last twelve months (peer median +6.6%); the operating margin is 9.9% (peer median 12.0%).

Valuation It trades at 5.6× enterprise value to sales against a peer median of 4.5× (9th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 34.2 points above its cost of capital (14.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 96ASTRAZEN.NS 70
Six months, rebased to 100: AstraZeneca Pharma India against the median of its 20 peers (local-currency closes).

AstraZeneca Pharma India financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹26.0B₹22.8B₹17.2B₹13.0B₹10.0B
Revenue growth—+33%+32%+29%—
Gross profit₹6.42B₹5.94B₹4.43B₹4.32B₹3.55B
EBITDA₹2.78B₹2.66B₹2.58B₹1.87B₹1.67B
Net income₹1.78B₹1.88B₹1.16B₹1.62B₹993M
Free cash flown/a₹32.1M₹954M₹492M₹729M
Capital expendituren/a₹36.1M₹17.5M₹108M₹85.2M
Total debt₹962M₹1.11B₹357M₹45.9M₹72.1M

Quarterly statements and history in the cockpit →

AstraZeneca Pharma India competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%+20%000766ANURAS301047002755600420JUBLPHARMA0026751681002019300357SRPTINDGN600993CAPLIPOINT300723FAEMAZE688166ASTRAZEN.NS6-month return →1-month return →
Up and to the right = strong over both horizons. AstraZeneca Pharma India is the large dot.

Fundamentals: revenue growth against valuation

-100%-50%0%0×20×40×60×000766ANURAS301047002755600420JUBLPHARMA002019300357INDGNCAPLIPOINT300723MAZEASTRAZEN.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AstraZeneca Pharma India is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%0007663010470027556004200026751681300357SRPTINDGN600993CAPLIPOINT300723FAE688166600572ASTRAZEN.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AstraZeneca Pharma India is the large dot.

AstraZeneca Pharma India competitors and peer comparison

Head to head with its named competitors (ASTRAZEN.NS vs GLAXO.NS vs NOVARTIND.NS vs PFIZER.NS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
AstraZeneca Pharma India ASTRAZEN.NS$1.62B-30%+30%10%5.6×42.4%
GlaxoSmithKline Pharmaceuticals GLAXO.NS$4.79B+10%+12%33%10.2×26.4%
Novartis India NOVARTIND.NSn/a+67%n/an/an/an/a
Pfizer PFIZER.NS$1.88B-20%+12%34%5.5×11.2%

How AstraZeneca Pharma India compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AstraZeneca Pharma India against its 20 peers (data as of 18 Nov 2026)
MeasureASTRAZEN.NSPeer medianRank in peer set
1-month return+0.1%-3.9%6th highest of 21
6-month return-30.5%-3.7%5th lowest of 20
Distance from 52-week high-36.2%-33.8%11th highest of 21
Revenue growth (TTM)+29.7%+6.6%3rd highest of 20
Operating margin9.9%12.0%10th lowest of 20
EV / Sales5.6×4.5×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)42.4%11.3%most demanding of 16
Growth delivered (Del g)+23.0%+6.8%3rd highest of 16
Hurdle (Req g minus delivered)+19.5 pp+7.6 pp6th most demanding of 16
ROIC minus cost of capital+34.2 pp-1.0 pp2nd highest of 21
EV / EBITDA52.6×17.1×most expensive of 7
Net debt / EBITDA-1.7×1.9×2nd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%5.6×42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%12.2×33.0%+0.9%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%7.2×n/an/a
Sino Biological 301047.SZChina$1.60B+27%+20%17%9.8×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%5.2×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%1.2×-6.6%-5.6%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%2.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%4.5×6.0%-4.3%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%2.2×-14.9%+13.5%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%2.5×n/an/a
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%8.9×18.4%+10.8%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%0.9×-6.8%+32.4%
Indegene INDGN.NSIndia$1.69B+28%+36%12%3.6×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%2.3×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%6.3×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%16.7×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%2.6×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%68.8×n/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%9.7×35.3%+9.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%

Questions

Who are AstraZeneca Pharma India's main competitors?
Named competitors: GSK Pharma India (GLAXO.NS), Novartis India (NOVARTIND.NS), Pfizer India (PFIZER.NS). The cockpit's measured peer set (industry) also includes Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ), Anupam Rasayan India (ANURAS.NS), Sino Biological (301047.SZ), Beijing Aosaikang Pharmaceutical (002755.SZ), Shanghai Shyndec Pharmaceutical (600420.SS), Jubilant Pharmova (JUBLPHARMA.NS).
Is AstraZeneca Pharma India expensive compared with its peers?
On ev / sales it trades at 5.6× against a peer median of 4.5×, 9th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has AstraZeneca Pharma India stock performed?
Over six months to 18 Nov 2026 the shares returned -30.5% against -3.7% for the median peer; over one year -34.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.